PBI-4050, Prometic Life Sciences’ lead therapy candidate, works through a dual mechanism to target a newly discovered pathway, involving the receptors GPR40 and GPR84, that is critical to fibrosis development, a study shows. The study, “A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors:…
Prometic’s PBI-4050 Plays Dual Role in Targeting New Antifibrotic Pathway, Study Says
If you have read my previous columns, you are likely aware that my life before being diagnosed with idiopathic pulmonary fibrosis (IPF) was very different than it is now. This is something I often write about because I can’t believe the dramatic transformation from who I was…
An enzyme can start a chain of events that leads to cells involved in tissue scarring reversing their fibrosis-generating activity, British and American researchers have discovered. The study dealt with the enzyme’s effect on myofibroblasts — cells involved in wound healing and inflammatory response. The discovery could lead to new therapies for the lung scarring…
Kadmon’s KD025 slowed the progression of idiopathic pulmonary fibrosis and patients’ decline in lung function, a Phase 2 clinical trial shows. The IPF patients in the open-label trial (NCT02688647) had previously been treated with Genentech’s Esbriet (pirfenidone) or Boehringer Ingelheim’s Ofev (nintedanib) — or had…
Living with a life-threatening illness like idiopathic pulmonary fibrosis (IPF) evokes a plethora of feelings throughout the course of the disease. Some are positive. At times, a patient is content, grateful, or hopeful. Other times, the feelings are negative and a patient could experience anger, fear, guilt, or…
patientMpower, a U.K. digitial healthcare and advocacy company, joined others in voicing disappointment with the recent decision of a British advisory board to restrict the use of Esbriet (pirfenidone) to patients with moderate-to-severe idiopathic pulmonary fibrosis (IPF). NICE’s final recommendations for Esbriet (marketed by Genentech) and its…
Using supplemental oxygen is a mixed bag. It is wonderful because it gives us the oxygen we need to keep our body healthy and to stay alive. It is hard due to many reasons I shared in a previous column, including dealing with the tubing. I’ve discovered…
Pulmonary fibrosis patients have a new tool for learning about clinical trials of potential treatments. The Clinical Trial Finder is an online platform that the Pulmonary Fibrosis Foundation developed. It offers information on the more than 100 research opportunities listed on the National Institutes of Health’s ClinicalTrials.gov website. An overarching goal…
At some point, everyone experiences a level of vulnerability. Perhaps it is joining a new sports team as a child where you fear your skills may not be comparable to other members of the team. Maybe it is on a first date where there is a risk that…
Swiss researchers have identified a potential blood biomarker for idiopathic pulmonary fibrosis — a precursor to the signaling molecule lysophosphatidic acid. Their study, ”Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis – a potential biomarker role for LysoPC,” was published in the journal…
